

Specialty Guideline Management

Ojemda

Products Referenced by this Document

Drugs that are listed in the following table include both brand and generic and all dosage forms and strengths unless otherwise stated. Over-the-counter (OTC) products are not included unless otherwise stated.

Brand Name	Generic Name
Ojemda	tovorafenib

Indications

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy

FDA-approved Indications¹

Treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation.

Compendial Uses²

- Central Nervous System (CNS) Cancers
 - Circumscribed glioma – WHO grade 1 or 2
 - Pleomorphic xanthoastrocytoma – WHO grade 2
- Langerhans Cell Histiocytosis (LCH)

All other indications are considered experimental/investigational and not medically necessary.

Documentation

Submission of the following information is necessary to initiate the prior authorization review: medical record documentation of activating BRAF alteration.

Coverage Criteria

Central Nervous System (CNS) Cancers^{1,2}

Authorization of 12 months may be granted for treatment of CNS cancers harboring a BRAF fusion or rearrangement, or BRAF V600 mutation, as a single agent, when either of the following criteria are met:

- Member is 6 months of age and older with relapsed or refractory pediatric low-grade glioma
- Member has recurrent or progressive, WHO grade 1 or 2 circumscribed glioma or WHO grade 2 pleomorphic xanthoastrocytoma

Langerhans Cell Histiocytosis (LCH)²

- Authorization of 12 months may be granted for treatment of LCH with BRAF alterations, as a single agent.

Continuation of Therapy

Authorization of 12 months may be granted for continued treatment in members requesting reauthorization for an indication in the Coverage Criteria section when there is no evidence of unacceptable toxicity or disease progression while on the current regimen.

References

1. Ojemda [package insert]. Brisbane, CA: Day One Biopharmaceuticals, Inc.; August 2025.
2. The NCCN Drugs & Biologics Compendium® © 2026 National Comprehensive Cancer Network, Inc. Available at: <https://www.nccn.org>. Accessed May 11, 2026.